The newly announced dividend is will be paid on Friday, February 13th. Stockholders of record on Monday, February 2nd will be paid a dividend of $0.20 per share
A number of analysts have recently weighed in on VIVO shares. Analysts at Craig Hallum upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating and raised their price
The stock has a 50-day moving average of $16.67 and a 200-day moving average of $18.17. The company
Meridian Bioscience (NASDAQ:VIVO) last released its earnings data on Thursday, January 22nd. The company reported $0.19 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.19. The company had revenue of $48.00 million for the quarter, compared to the consensus estimate of $46.20 million. Analysts expect that Meridian Bioscience will post $0.86 EPS for the current fiscal year.
Meridian Bioscience, Inc (NASDAQ:VIVO) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies